17. TERM AND TERMINATION.
17.1 Termination Prior to the Closing Date.
This Agreement may be terminated at any time prior to the Closing Date (with respect to Sections 17.1(b) and 17.1(c) below, by written notice by the terminating Party to the other Party): (a) by mutual written agreement of the Parties;
(b) by Licensor or Licensee, if a court of competent jurisdiction or other Governmental Authority shall have issued a non-appealable final order, decree or ruling or taken any other non-appealable final action, in each case, having the effect of permanently restraining, enjoining or otherwise prohibiting the transactions contemplated by this Agreement; provided, however, that the right to terminate this Agreement under this Section 17.1(b) shall not be available to any Party whose failure to fulfill any obligation under this Agreement has been the primary cause of, or materially contributed to, such action; or
(c) by Licensee, if Licensor has breached any representation, warranty, covenant or agreement of Licensor set forth in this Agreement which (i) would result in a failure of a condition set forth in Section 13.2 and (ii) is not cured within thirty (30) calendar days after written notice thereof.
17.2 Term.
Except as provided in Section 17.1, this Agreement shall continue until the date of expiration of the Royalty Term, unless earlier terminated in accordance with this Article 17 (the “Term”).
17.3 Termination of the Agreement After the Closing Date.
(a) Termination by Licensee.
Licensee may terminate this Agreement in its entirety or in part (including, for example, on a country-by-country basis) for any reason (a) upon at least ninety (90) days prior written notice to Licensor if such notice is delivered prior to the First Commercial Sale of a Licensed Product anywhere in the Territory or (b) upon at least one hundred eighty (180) days prior written notice to Licensor if such notice is delivered after the First Commercial Sale of a Licensed Product anywhere in the Territory. In the event of any significant adverse clinical events or the termination of a Clinical Trial for safety reasons and Licensee terminates this Agreement under this Section 17.3(a), the foregoing notice periods in clauses (a) and (b) shall be reduced to forty-five (45) days and ninety (90) days, respectively.
(b) Termination for Material Breach.
If either Party believes the other is in material breach of its obligations under this Agreement, it may give notice of such breach to the other Party, which Party shall have sixty (60) days in which to remedy such breach, or thirty (30) days in the case of material breach of any payment obligation hereunder.
Such sixty (60) day period shall be extended in the case of a breach not capable of being remedied in such sixty (60) day period so long as the breaching Party uses diligent efforts to remedy such breach and is pursuing a course of action that, if successful, will effect such a remedy; provided, however, that such cure period shall not be extended more than sixty (60) additional days.
If such alleged breach is not remedied or is not capable of being remedied within the period set forth above, the non-breaching Party shall be entitled, without prejudice to any of its other rights conferred on it by this Agreement, and in addition to any other remedies available to it by law or in equity, to terminate this Agreement upon written notice to the other Party. In the event of a dispute regarding any payments due and owing hereunder, all undisputed amounts shall be paid when due and the balance, if any, shall be paid promptly after settlement of the dispute including any accrued interest thereon.
(c) Consequences of Termination.
In the event that either Party terminates this Agreement, then as of the effective date of such termination, the following terms and conditions shall apply:
(i) Termination by Licensor for Licensee’s Material Breach.
In the event of termination of this Agreement by Licensor pursuant to Section 17.3(b) for Licensee’s uncured material breach, and except for each Party’s rights and obligations that survive termination as set forth in Section 17.5:
(A) all licenses and rights granted by either Party under this Agreement shall terminate with the exception, subject to Section 19.1, of the license granted to Licensor by Licensee under the Licensee Inventions relating to formulations or methods of manufacturing formulations derived from the Licensed Intellectual Property pursuant to Section 9.2(c) which shall become perpetual, worldwide and fully paid;
(B) Licensee shall pay Licensor any and all payments that have accrued prior to the effective date of such termination;
(C) Licensee shall transfer to Licensor all materials, results, analyses, reports, websites, marketing materials, technology, know-how and other Information in whatever form received by Licensee from Licensor as of the effective date of such termination;
(D) Licensee shall transfer to Licensor (A) all Regulatory Approvals in the Territory in effect as of the date of such termination and/or (B) any and all Information pertaining to the Development and Commercialization of the Licensed Products in the Territory, including but not limited to any and all Clinical Trial data pertaining to the Territory.
(ii) Termination by Licensee.
Subject to Section 17.3(c)(ii)(E), in the event of termination of this Agreement by Licensee pursuant to Section 17.3(a), and except for each Party’s rights and obligations that survive termination as set forth in Section 17.5:
(A) all licenses and rights granted by either Party under this Agreement shall terminate, with the exception, subject to Section 19.1, of the license granted to Licensor by Licensee under the Licensee Inventions relating to formulations or methods of manufacturing formulations derived from the Licensed Intellectual Property pursuant to Section 9.2(c), which shall become worldwide, subject to Licensor’s obligations under subsection (E) below;
(B) Licensee shall pay Licensor any and all payments that have accrued prior to the effective date of such termination;
(C) Licensee shall transfer to Licensor all materials, results, analyses, reports, websites, marketing materials, technology, know-how and other Information in whatever form received by Licensee from Licensor as of the effective date of such termination;
(D) Licensee shall, upon receipt of reasonable consideration from Licensor based on an actual cost basis, transfer to Licensor (A) all Regulatory Approvals in the Territory in effect as of the date of such termination and/or (B) any and all Information pertaining to the Development and Commercialization of the Licensed Products in the Territory, including but not limited to any and all Clinical Trial data pertaining to the Territory; and
(E) in partial consideration for (A) Licensee’s costs of obtaining and maintaining such Regulatory Approvals and Commercializing Licensed Products in the Territory prior to the date of such termination, and/or (B) subject to Section 19.1, the license granted under the Licensee Inventions, Licensor shall pay to Licensee following the effective date of such termination, on a product-by-product and country-by-country basis, a commercially reasonable royalty to be negotiated in good faith by the Parties, on all sales by Licensor, its Affiliates and Sublicensees, of products that would have been Licensed Products, had they been sold by Licensee prior to the effective date of such termination.
(iii) Termination by Licensee for Licensor’s Material Breach.
In the event that Licensee has the right to terminate this Agreement for Licensor’s uncured material breach pursuant to Section 17.3(b), Licensee may terminate this Agreement or, in lieu of such termination, by written notice to Licensor after a determination that such breach was a material breach and was not cured before the expiration of the cure period set forth in Section 17.3(b), elect to retain all of the rights and licenses granted to Licensee hereunder for the remainder of the Term. Following such an election by Licensee:
(A) Licensee may request that damages be awarded to Licensee for Licensor’s uncured material breach by final and binding arbitration conducted in accordance with Section 19.12. In determining whether damages should be awarded to Licensee, the arbitrators shall consider the nature of Licensor’s uncured material breach and the impact of such uncured material breach on Licensee and the transactions contemplated by this Agreement.
In the event that such final and binding arbitration determines that Licensee should be awarded damages, Licensee shall be entitled to deduct the amount of such damages from milestone and royalty payments to be paid to Licensor under Sections 8.2 and 8.3;
(B) the limitations applicable to Licensor’s activities as set forth in Sections 2.3(a) and 2.4 shall continue to apply; and
(C) the license granted by Licensee to Licensor under Section 9.2(c) shall terminate.
17.4 Surviving Obligations.
Upon termination of this Agreement, the Parties shall remain obligated to make all payments which have accrued under this Agreement prior to the date of termination, when and as they become due and payable. In addition, the provisions in Articles 1, 9, 10, 14, 15, 16, 18 and 19, and Sections 2.6, 5.2, 5.7, 7.6, 8.3(h), 8.7 (with respect to payment accruing prior to the effective date of termination), 8.8, 8.9, 17.3(c), 17.4 and 17.5 of this Agreement shall survive termination of this Agreement for any reason.
17.5 Accrued Rights.
Termination or expiration of this Agreement shall not relieve either Party from obligations that are expressly indicated to survive termination or expiration of the Agreement. Termination by a Party shall not be an exclusive remedy and all other remedies will be available to the terminating Party, in equity and at law.
KASAN_국제계약, 영문계약, 특허실시, 영업비밀, 기술이전 라이선스 계약서에서 계약종료, 계약해지, TERMINATION 영문조항 샘플.pdf
ARTICLE 2 - TECHNICAL ASSISTANCE
2.1 TECHNICAL DOCUMENTATION
(a) Licensor shall furnish to Licensee, in accordance with the time schedule to be agreed upon between the Parties, one (1) set of hard copies of the Technical Documentation. If Licensee discovers that any of the documents are missing or illegible or damaged, Licensee shall inform Licensor in writing and Licensor shall make such documents available for Licensee within twenty (20) days of receiving such notice.
(b) The foregoing Technical Documentation to be furnished under paragraph 2.1 (a) above shall be delivered to Licensee and shall be the latest version as of the time it is delivered or sent.
(c) Licensee shall pay Licensor for any additional copies of the Technical Documentation requested by Licensee at the rates agreed upon in writing by both Parties prior to sending.
(d) Nothing in this Agreement shall be construed to require that Licensor furnish Licensee with any technical information on any products other than Licensed Product or any technical information which may not be furnished because of a government contract, act, regulation or restriction or the proprietary interest of a third party.
(e) Errors in Technical Documentation. Each Party shall promptly advise the other of any significant error it may discover in the Technical Documentation. In that event, Licensor shall correct any error in the Technical Documentation and shall furnish such corrected Technical Documentation to Licensee without charge.
(f) Strict Compliance with Technical Documentation. In order to maintain the quality of the Licensed Products manufactured and assembled by Licensee pursuant to this Agreement, Licensee shall manufacture and/or assemble the Licensed Products in strict accordance with the standards and specifications stated in the Technical Documentation provided by Licensor and as otherwise specified by Licensor. Licensee shall exercise the utmost care in the selection of the materials and parts to be used and incorporated into the Licensed Products.
2.2 ASSISTANCE BY LICENSOR
Licensor shall provide reasonable assistance in the use of the Technical Documentation to the extent such assistance is reasonably necessary for Licensee to make use of the Technical Documentation to manufacture the Licensed Product. Such assistance may include, but will not be limited to, technical assistance, training, testing and limited application engineering services.
- 라이센서의 조력의무를 선언적으로 규정한 조항임. 제조에 필요한 기술정보 활용을 가능케 하도록 조력의무를 규정하고 있어 상당히 포괄적임.
- 이하에서 구제적인 비용을 규정할 경우 라이센서의 수입원이 되지만, 그렇지 않을 경우 부담조항이 될 수 있음.
2.3 TECHNICAL ASSISTANCE
(a) At the request of Licensee, Licensor shall, at times agreed upon by the Parties, dispatch its engineers to Licensee to provide technical assistance on matters concerning the use of the Technical Documentation during the Technical Cooperation Period. All costs and expenses of such Licensor's personnel dispatched to Licensee shall be borne, or reimbursed to Licensor, by Licensee and shall include:
(i) round trip economic air fare between Korea and China;
(ii) suitable accommodations, meals, traveling and transportation expenses in China and other reasonable charges in connection with the performance of their duties hereunder;
(iii) wage and daily allowance, payable to Licensor, on its demand, amounting to U$500 per Man Day for Licensor's personnel;
(b) Licensee shall take appropriate steps necessary to protect and ensure the safety of Licensor's personnel and their property, including without limitation, against war, war-like operation, terror, revolution, civil commotion, catastrophe and acts of public enemies. Licensor reserves the right to instruct any or all of its dispatched personnel to return to Korea, or such other place as it may designate, at Licensee's expense when, in Licensor's sole judgment , one of the above-mentioned situations arises which may endanger the safety and well-being of such personnel.
- 기술자 파견에 따른 안전보장은 실시자 부담임
(c) Licensee is responsible for obtaining any permits or authorizations required for Licensor's personnel to enter China to provide services hereunder, and to bring any related materials required by Licensor.
- 기술자 파견에 따른 출입국 보장은 실시자 부담
(d) The number of such personnel, the period of their stay at Licensee's plant and other terms and conditions not set forth herein shall be agreed upon between the Parties on a case by case basis.
2.4 TRAINING
At the request of Licensee, Licensor will, during the Technical Cooperation Period, provide training on the use of the Technical Documentation for Licensee's employees (the "Trainees") at Licensor's place or other places designated by Licensor, subject to the following terms and conditions:
(i) Licensor and Licensee shall agree on the most efficient training program for the Trainees;
(ii) Licensee shall bear all the cost and expenses relating to the Trainees, including but not limited to their salaries, round trip airfare between China and Korea, lodgings and meals of Trainees in Korea, transportation and insurance;
(iii) Licensor shall provide working lunches for the trainees during working days and transportation for the trainees between dormitory and training site.
(iv) Licensee shall pay to Licensor as training fee, payable upon demand, US$300 per Trainee per day, as the compensation of training services provided by Licensor;
(v) Licensee shall instruct the Trainees to observe and abide by all rules and regulations of Licensor and the laws of Korea during their training period;
(vi) All Trainees shall be insured at the expense of Licensee by an internationally recognized accident compensation insurance during the entire training period between their departure from and return to China;
(vii) Licensee shall indemnify and hold harmless Licensor against any loss, damage, claim, liabilities, cost or expense arising out of any act of a Trainee or any injury or death of the Trainee or any damage to his/her property.
2.5 SUPPORT OF TESTS
Pursuant to the terms of a purchase order, sale agreement or other document to be separately agreed by the Parties or Licensee and Delphi, Licensor will support the necessary manufacturing Part Production Approval Process validation tests for the Licensed Products.
2.6 SAMPLE TEST AND VERIFICATION
Before distribution and sale of any of the Licensed Product manufactured or assembled hereunder, Licensee shall submit, at its expense, samples of the Licensed Product for approval by Licensor. Licensor shall promptly conduct appropriate tests on such samples and advise Licensee of the results thereof. The costs of any tests on the samples shall be responsibility of Licensee, and Licensor shall advise Licensee of the test fees in advance.
KASAN_국제계약, 영문계약, 특허실시, 영업비밀, 기술이전 라이선스 계약서에서 기술지원 TECHNICAL ASSISTANCE 조항 샘플.pdf
대법원 2017. 5. 11. 선고 2014두8773 판결
행정법규 위반에 대한 제재조치는 행정목적의 달성을 위하여 행정법규 위반이라는 객관적 사실에 착안하여 가하는 제재이므로, 반드시 현실적인 행위자가 아니라도 법령상 책임자로 규정된 자에게 부과되고, 특별한 사정이 없는 한 위반자에게 고의나 과실이 없더라도 부과할 수 있다.
대법원 2012. 6. 28. 선고 2010두24371 판결
행정법규 위반에 대하여 가하는 제재조치는 행정목적의 달성을 위하여 행정법규 위반이라는 객관적 사실에 착안하여 가하는 제재이므로, 위반자가 그 의무를 알지 못하는 것이 무리가 아니었다고 할 수 있어 그것을 정당시할 수 있는 사정이 있을 때 또는 의무의 이행을 당사자에게 기대하는 것이 무리라고 하는 사정이 있을 때 등 의무 해태를 탓할 수 없는 정당한 사유가 있는 경우 등의 특별한 사정이 없는 한 위반자에게 고의나 과실이 없다고 하더라도 부과될 수 있다.
대법원 2014. 12. 24. 선고 2010두6700 판결
행정법규 위반에 대하여 가하는 제재조치는 행정목적의 달성을 위하여 행정법규 위반이라는 객관적 사실에 착안하여 가하는 제재이므로 위반자의 고의·과실이 있어야만 하는 것은 아니나, 그렇다고 하여 위반자의 의무 해태를 탓할 수 없는 정당한 사유가 있는 경우까지 부과할 수 있는 것은 아니다(대법원 1976. 9. 14. 선고 75누255 판결, 대법원 2003. 9. 2. 선고 2002두5177 판결 등 참조).
서울고등법원 2016. 12. 15. 선고 2016누44508 판결
행정법규 위반에 대하여 가하는 제재조치는 행정목적의 달성을 위하여 행정법규 위반이라는 객관적 사실에 착안하여 가하는 제재이므로 반드시 현실적인 행위자가 아니라도 법령상 책임자로 규정된 자에게 부과되고 특별한 사정이 없는 한 위반자에게 고의나 과실이 없더라도 부과할 수 있는 것인바(대법원 2012. 5. 10. 선고 2012두1297 판결 참조), 위 원고들이 내세우는 사유를 위 특별한 사유로 볼 수 없는 점, 행정 제재사유가 있어 제재처분을 하는 경우 어떠한 처분을 할 것인지는 제재권자의 재량에 맡겨진 것이고, 다만 제재권자가 그 재량권의 행사로서 한 제재처분이 사회통념상 현저하게 타당성을 잃어 제재권자에게 맡겨진 재량권을 남용한 것이라고 인정되는 경우에 한하여 그 처분을 위법한 것이라 할 것이고, 제재처분이 사회통념상 현저하게 타당성을 잃었다고 하려면 제재의 원인이 된 위반사실의 내용과 성질, 제재에 의하여 달성하려고 하는 행정목적, 제재 양정의 기준 등 여러 요소를 종합하여 판단할 때에 그 제재 내용이 객관적으로 명백히 부당하다고 인정할 수 있는 경우라야 할 것이다(대법원 2002. 9. 24. 선고 2002두6620 판결 등 참조).
서울고등법원 2014. 11. 26. 선고 2014누41635 판결
행정법규 위반에 대한 제재조치는 행정목적의 달성을 위해 행정법규 위반이라는 객관적 사실에 착안해서 가하는 제재이므로, 위반자에게 의무 이행을 기대하는 것이 무리인 사정이 있는 등 그 의무 해태를 탓할 수 없는 정당한 사유가 없는 한 위반자에게 고의나 과실이 없더라도 부과될 수 있다(대법원 2012. 6. 28. 선고 2010두24371 판결 등 참조).
사안의 개요
치과의사면허를 가진 피고인 2, 3이 치과의사면허를 가진 피고인 1로부터 명의를 빌려 각기 의료기관을 개설, 운영한 후 국민건강보험공단에 요양급여비용을 청구한 사안
쟁점 및 대법원 판결요지
의료인이 다른 의료인의 명의를 빌려 의료기관을 개설ㆍ운영하면서 국민건강보험공단으로부터 요양급여를 지급받은 경우, 위 공단을 피해자로 하는 사기죄가 성립하는지 여부 – 대법원 사기죄 부정
대법원 판결이유
비록 의료법 제4조 제2항은 의료인이 다른 의료인의 명의로 의료기관을 개설하거나 운영하는 행위를 제한하고 있으나, 이를 위반하여 개설ㆍ운영되는 의료기관도 의료기관 개설이 허용되는 의료인에 의하여 개설되었다는 점에서 제4조 제2항이 준수된 경우와 본질적 차이가 있다고 볼 수 없다.
또한 의료인이 다른 의료인의 명의로 의료기관을 개설ㆍ운영하면서 실시한 요양급여도 국민건강보험법에서 정한 요양급여의 기준에 부합하지 않는 등의 다른 사정이 없는 한 정상적인 의료기관이 실시한 요양급여와 본질적인 차이가 있다고 단정하기 어렵다.
의료법이 의료인의 자격이 없는 일반인이 제33조 제2항을 위반하여 의료기관을 개설한 경우와 달리, 제4조 제2항을 위반하여 의료기관을 개설․운영하는 의료인에게 고용되어 의료행위를 한 자에 대하여 별도의 처벌규정을 두지 아니한 것도 이를 고려한 것으로 보인다.
따라서 의료인으로서 자격과 면허를 보유한 사람이 의료법에 따라 의료기관을 개설하여 건강보험의 가입자 또는 피부양자에게 국민건강보험법에서 정한 요양급여를 실시하여 국민건강보험공단으로부터 요양급여비용을 지급받았다면, 설령 그 의료기관이 다른 의료인의 명의로 개설․운영되어 의료법 제4조 제2항을 위반하였다 하더라도 그 자체만으로는 국민건강보험법상 요양급여비용을 청구할 수 있는 요양기관에서 제외되지 아니하므로, 달리 요양급여비용을 적법하게 지급받을 수 없는 자격 내지 요건이 흠결되지 않는 한 국민건강보험공단을 피해자로 하는 사기죄를 구성한다고 할 수 없다.
첨부: 대법원 2019. 5. 30. 선고 2019도1839 판결
대법원 2019. 5. 30. 선고 2019도1839 판결.pdf
